Terms: = Lung cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Clinical Outcome
3 results:
1. Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.
Matsuzawa R; Morise M; Kinoshita F; Tanaka I; Koyama J; Kimura T; Kondoh Y; Tanaka T; Shima K; Hase T; Wakahara K; Ishii M; Hashimoto N
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3885-3893. PubMed ID: 36006483
[TBL] [Abstract] [Full Text] [Related]
2. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
Roszik J; Haydu LE; Hess KR; Oba J; Joon AY; Siroy AE; Karpinets TV; Stingo FC; Baladandayuthapani V; Tetzlaff MT; Wargo JA; Chen K; Forget MA; Haymaker CL; Chen JQ; Meric-Bernstam F; Eterovic AK; Shaw KR; Mills GB; Gershenwald JE; Radvanyi LG; Hwu P; Futreal PA; Gibbons DL; Lazar AJ; Bernatchez C; Davies MA; Woodman SE
BMC Med; 2016 Oct; 14(1):168. PubMed ID: 27776519
[TBL] [Abstract] [Full Text] [Related]
3. clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract] [Full Text] [Related]